Filana Therapeutics Inc (FLNA)

[aCryptoKing]

Cassava Sciences: Medical History In The Making

Summary

Despite a sophisticated and highly profitable short attack, Cassava
Sciences will commence two phase 3 trials shortly.

Prior to October 1st, Cassava should release 12-month cognition data that we anticipate will be consistent with the 9-month data (ADAS-Cog11 range of -2.5 to -3.5+).

This will be the first drug ever to show improvement at 12 months and that data will be independently collected & interpreted.

There is no placebo effect at 12 months.

Simufilam can become the new standard of care over Aricept given its superior safety and efficacy.

--------------------------------------------------------------------

Setup

On July 29th, Cassava Sciences (SAVA) presented the best cognition and biomarker data that has ever been presented in the history of Alzheimer's disease research. The data blew away every projection by Wall Street analysts. With the benefit of hindsight, the CEO clearly and repeatedly telegraphed that they would be presenting historic data on July 29th. Despite the uniqueness and historic nature of the data presented, short-sellers, profit-takers, and investors "selling the news" combined to drive down the value of the company by ~50% on July 29th and 30th.

The stock subsequently rebounded by >70% from July 29th to August 13th. Then on August 24th, anonymous short-sellers initiated another attack in the form of a Citizen's Petition filed with the FDA along with multiple supplements to the original petition coming in the following days and weeks. This petition has created tremendous doubt and confusion. The stock price of Cassava has suffered accordingly falling from ~$117 on August 24th to ~$48 on September 17th.

Cassava Sciences' management team has been attacked on both a personal and professional level. To date, their responses have been watered down. Cassava's lawyers must have restrained them from responding forcefully. However, the company will not be muzzled forever. ....

Continued: https://seekingalpha.com/article/4456304-cassava-sciences-medical-history-in-the-making


NEWS TODAY (confirming the speculation):
https://www.globenewswire.com/news-release/2021/09/22/2301328/8339/en/Cassava-Sciences-Announces-Top-line-Results-of-12-month-Interim-Analysis-from-Open-label-Study-Evaluating-Simufilam-in-Alzheimer-s-Disease.html